PURPOSE: ALLRT is a longitudinal cohort study of HIV-infected subjects prospectively randomized into selected clinical trials for antiretroviral (ARV) treatment-naïve and ARV treatment-experienced individuals conducted by the AIDS Clinical Trials Group (ACTG). We describe the rationale, design, and baseline characteristics of the ALLRT cohort and its potential to address important research questions related to ARV therapy. METHOD: Standardized visits occur every 16 weeks to evaluate long-term clinical, virologic, and immunologic outcomes associated with ARV treatment. RESULTS: A total of 4,371 subjects enrolled in ALLRT from January 2000 through June 2007. Of these, 3,146 (72%) were ARV naïve at parent study entry (18% female, 44% white, 32% black, 21% Hispanic; median age 37 years, CD4 count 218 cells/microL, follow-up 3.6 years; 343 [11%] followed > or = 8 years) and 1,225 (28%) were treatment experienced (13% female, 59% white, 20% black, 17% Hispanic; median age 42 years, CD4 count 325 cells/microL, follow-up 5.7 years). CONCLUSIONS: ALLRT provides the opportunity to understand long-term ramifications of therapeutic ARV choices and determine whether these vary by treatment regimen, timing of treatment initiation, or treatment changes over long-term follow-up. Investigations based on uniform data and specimen collection in the context of randomized ARV treatments will be critical to developing more successful long-term therapeutic strategies for HIV treatment.
PURPOSE: ALLRT is a longitudinal cohort study of HIV-infected subjects prospectively randomized into selected clinical trials for antiretroviral (ARV) treatment-naïve and ARV treatment-experienced individuals conducted by the AIDS Clinical Trials Group (ACTG). We describe the rationale, design, and baseline characteristics of the ALLRT cohort and its potential to address important research questions related to ARV therapy. METHOD: Standardized visits occur every 16 weeks to evaluate long-term clinical, virologic, and immunologic outcomes associated with ARV treatment. RESULTS: A total of 4,371 subjects enrolled in ALLRT from January 2000 through June 2007. Of these, 3,146 (72%) were ARV naïve at parent study entry (18% female, 44% white, 32% black, 21% Hispanic; median age 37 years, CD4 count 218 cells/microL, follow-up 3.6 years; 343 [11%] followed > or = 8 years) and 1,225 (28%) were treatment experienced (13% female, 59% white, 20% black, 17% Hispanic; median age 42 years, CD4 count 325 cells/microL, follow-up 5.7 years). CONCLUSIONS: ALLRT provides the opportunity to understand long-term ramifications of therapeutic ARV choices and determine whether these vary by treatment regimen, timing of treatment initiation, or treatment changes over long-term follow-up. Investigations based on uniform data and specimen collection in the context of randomized ARV treatments will be critical to developing more successful long-term therapeutic strategies for HIV treatment.
Authors: Alan L Landay; John Spritzler; Harold Kessler; Donna Mildvan; Minya Pu; Larry Fox; Dorothy O'Neil; Barbara Schock; Daniel Kuritzkes; Michael M Lederman Journal: J Infect Dis Date: 2003-11-13 Impact factor: 5.226
Authors: Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Robert W Shafer; Laura M Smeaton; Gregory K Robbins; Victor De Gruttola; Sally W Snyder; Richard T D'Aquila; Victoria A Johnson; Gene D Morse; Mostafa A Nokta; Ana I Martinez; Barbara M Gripshover; Pamposh Kaul; Richard Haubrich; Mary Swingle; S Debra McCarty; Stefano Vella; Martin S Hirsch; Thomas C Merigan Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: Robert C Kalayjian; Nora Franceschini; Samir K Gupta; Lynda A Szczech; Ezekiel Mupere; Ronald J Bosch; Marlene Smurzynski; Jeffrey M Albert Journal: AIDS Date: 2008-02-19 Impact factor: 4.177
Authors: Sharon A Riddler; Hongyu Jiang; Allan Tenorio; Hairong Huang; Daniel R Kuritzkes; Edward P Acosta; Alan Landay; Barbara Bastow; David W Haas; Karen T Tashima; Mamta K Jain; Steven G Deeks; John A Bartlett Journal: Antivir Ther Date: 2007
Authors: Lynn E Taylor; Marisa Holubar; Kunling Wu; Ronald J Bosch; David L Wyles; John A Davis; Kenneth H Mayer; Kenneth E Sherman; Karen T Tashima Journal: Clin Infect Dis Date: 2011-01-31 Impact factor: 9.079
Authors: Konstantia Angelidou; Peter W Hunt; Alan L Landay; Cara C Wilson; Benigno Rodriguez; Steven G Deeks; Ronald J Bosch; Michael M Lederman Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Hamza Coban; Kevin Robertson; Marlene Smurzynski; Supriya Krishnan; Kunling Wu; Ronald J Bosch; Ann C Collier; Ronald J Ellis Journal: AIDS Date: 2017-07-17 Impact factor: 4.177
Authors: Heather J Ribaudo; Constance A Benson; Yu Zheng; Susan L Koletar; Ann C Collier; Judith J Lok; Marlene Smurzynski; Ronald J Bosch; Barbara Bastow; Jeffrey T Schouten Journal: Clin Infect Dis Date: 2011-04-01 Impact factor: 9.079
Authors: Supriya Krishnan; Jeffrey T Schouten; Denise L Jacobson; Constance A Benson; Ann C Collier; Susan L Koletar; Jorge Santana; Fred R Sattler; Ronald Mitsuyasu Journal: Oncology Date: 2011-05-23 Impact factor: 2.935
Authors: Judith J Lok; Peter W Hunt; Ann C Collier; Constance A Benson; Mallory D Witt; Amneris E Luque; Steven G Deeks; Ronald J Bosch Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas Journal: Clin Infect Dis Date: 2013-02-05 Impact factor: 9.079
Authors: Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick Journal: Clin Infect Dis Date: 2013-09-17 Impact factor: 9.079
Authors: Jordan E Lake; Kunling Wu; Sara H Bares; Paula Debroy; Catherine Godfrey; John R Koethe; Grace A McComsey; Frank J Palella; Katherine Tassiopoulos; Kristine M Erlandson Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079
Authors: Xinyan Zhang; Peter W Hunt; Scott M Hammer; Michelle S Cespedes; Kristine B Patterson; Ronald J Bosch Journal: HIV Clin Trials Date: 2013 Mar-Apr